Mesoblast Limited (MESO): Price and Financial Metrics

Mesoblast Limited (MESO)

Today's Latest Price: $12.83 USD

0.18 (1.42%)

Updated May 29 4:00pm

Add MESO to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 214 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

MESO Stock Summary

  • The capital turnover (annual revenue relative to shareholder's equity) for MESO is 0.03 -- better than just 10.03% of US stocks.
  • MESO's one year PEG ratio, measuring expected growth in earnings next year relative to current common stock price is 4,006.76 -- higher than 99.09% of US-listed equities with positive expected earnings growth.
  • With a price/sales ratio of 76.51, Mesoblast Ltd has a higher such ratio than 97.21% of stocks in our set.
  • If you're looking for stocks that are quantitatively similar to Mesoblast Ltd, a group of peers worth examining would be JKHY, DRRX, FOXF, LQDT, and TCX.
  • MESO's SEC filings can be seen here. And to visit Mesoblast Ltd's official web site, go to
MESO Daily Price Range
MESO 52-Week Price Range

MESO Stock Price Chart More Charts

MESO Price/Volume Stats

Current price $12.83 52-week high $20.57
Prev. close $12.65 52-week low $3.12
Day low $12.66 Volume 546,378
Day high $13.15 Avg. volume 739,092
50-day MA $8.38 Dividend yield N/A
200-day MA $7.29 Market Cap 1.49B

Mesoblast Limited (MESO) Company Bio

Mesoblast Ltd. has established a diverse portfolio of product candidates based on its proprietary allogeneic, off-the-shelf mesenchymal lineage cell-based technology, with multiple active Phase 3 clinical programs. Mesoblast's lead product candidates target major diseases with significant unmet medical needs despite existing therapies. These include chronic heart failure, chronic low back pain due to degenerative disc disease, and immune-mediated conditions such as acute graft versus host disease and biologic refractory rheumatoid arthritis. The company is based in Melbourne, Australia.

MESO Latest News Stream

Event/TimeNews Detail
Loading, please wait...

MESO Latest Social Stream

Loading social stream, please wait...

View Full MESO Social Stream

Latest MESO News From Around the Web

Below are the latest news stories about Mesoblast Ltd that investors may wish to consider to help them evaluate MESO as an investment opportunity.

Mesoblast Limited 2020 Q3 - Results - Earnings Call Presentation

The following slide deck was published by Mesoblast Limited in conjunction with their 2020 Q3 earnings call....

SA Transcripts | May 28, 2020

Mesoblast Limited (MESO) Q3 2020 Earnings Call Transcript

Hello, and welcome to the financial results for the period ended March 31, 2020, and corporate update for Mesoblast. Before we begin, let me remind you that in today's conference call the company will be making forward-looking statements that represent the company's intentions, expectations or beliefs concerning future events. In addition, any forward-looking statements represent the company's views only as of the date of this webcast and should not be relied upon as representing the company's views of any subsequent date.

Yahoo | May 28, 2020

Mesoblast (ASX:MSB) reports a net loss US$45.3 million for nine months

28 May 2020 - Mesoblast (ASX:MSB), the company that develops cellular medicines for inflammatory diseases, has reported a net loss of $US45.3 million in the nine months to the end of March.

Finance News Network | May 27, 2020

Mesoblast sees strong revenue growth as maintains busy clinical program with upcoming Ryoncil launch

In an interim performance update focusing on the past 9 months, dual-listed cellular medicines company Mesoblast (ASX: MSB) reported it had achieved a “strong financial position” and made progress with its lead drug remestemcel-L, a drug being developed to treat severe cytokine release syndromes.

Small Caps | May 27, 2020

Mesoblast Reports Strong Financial Position and Substantial Operational Progress For the Period Ended March 31, 2020

NEW YORK, May 27, 2020 -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today reported financial,.

Yahoo | May 27, 2020

Read More 'MESO' Stories Here

MESO Price Returns

1-mo 15.17%
3-mo 80.70%
6-mo 109.64%
1-year 170.11%
3-year 60.38%
5-year -13.54%
YTD 74.08%
2019 78.88%
2018 -29.45%
2017 9.16%
2016 -15.88%
2015 -64.19%

Continue Researching MESO

Here are a few links from around the web to help you further your research on Mesoblast Ltd's stock as an investment opportunity:

Mesoblast Ltd (MESO) Stock Price | Nasdaq
Mesoblast Ltd (MESO) Stock Quote, History and News - Yahoo Finance
Mesoblast Ltd (MESO) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.7716 seconds.